Home
/
Products
/
Services
/
Activity
/
Resource
/
News
/
Genomeditech
EN
EN
CN
Lentivirus
过表达慢病毒 干扰慢病毒
Cell Line Development
过表达细胞系构建服务 敲低细胞系构建服务 敲除细胞系构建服务 报告基因细胞株构建服务 Luciferase标记细胞株
Protein Expression
Plasmid DNA Preparation Services
过表达质粒构建 干扰质粒构建 突变/截短质粒构建 荧光素酶报告基因质粒构建
Adeno-associated Virus
过表达AAV 干扰AAV
Cell-based Assay
抗体Binding检测 蛋白/抗体药物功能检测 ADCC/P 活性检测 ADC药物CTG杀伤检测 CCK8细胞增值检测 克隆形成 细胞迁移/侵袭 细胞周期/凋亡 划痕实验
Antibody Services
Reporter Gene Detection Services
miRNA与靶基因调控研究 转录因子调控/promoter活性研究
Plasmid
Stock Plasmid Reporter Plasmid Autophagy Fluorescent Single-Tag Plasmid Empty Vector Cell Tracking Plasmid iPS-Related Plasmids
Cell Lines
Antibody Related Cell Tracing Cytokines GPCR Immune Checkpoint Immunology In Vivo Imaging Kinase Metabolism Molecular-Reference-Standards Nuclear Receptors PRR Signalings Pseudovirus TLR TNF Superfamily Transcription Factor Tumor-Associated Antigen(TAA) Others
Molecular Reference Standards
gDNA ctDNA
Reporter gene detection-related reagents
GMOne-Step GMOne-Step 2.0 GMBright One-Step GMSteady One-Step Dual Luciferase Reporter Gene Assay Kit D-Luciferin
Lentivirus
Overexpression Lentivirus Reporter Lentivirus In Vivo Imaging Lentivirus iPS-Related Lentivirus Immortalization Lentivirus Autophagy Lentivirus Cre Lentivirus Fluorescent Control Lentivirus
Proteins
ADC Internalization Antibody Related Cytokines GPCR Immune Checkpoint Immunology Kinase Metabolism Others PRR signalings Tumor-Associated Antigen(TAA) TNF Superfamily
Pseudovirus control material
Coronavirus-Like Pseudovirus Influenza-Like Pseudovirus Parainfluenza-Like Pseudovirus Respiratory Syncytial Virus-Like Pseudovirus Rhinovirus-Like Pseudovirus Human Metapneumovirus-Like Pseudovirus Monkeypox-Like Pseudovirus
Reagents related to cell function detection and analysis
GMTiter TM Luminescent Cell Viability Assay Cell Counting kit-8
Adeno-Associated Virus (AAV)
Optogenetics Chemical Genetics Calcium Imaging Cre Recombinase Standard Control Vectors
Antibodies
Biosimilar Antibodies ADC Antibodies In Vivo MAb Antibodies Virus neutralizing antibodies Antibody Related Tag Antibodies/Loading Controls Antibodies
Pseudovirus
SARS-CoV-2 pseudovirus Rabies Pseudovirus SARS Pseudovirus Influenza pseudovirus MERS pseudovirus HIV-1 Pseudovirus
Genoagent (Brand name of reagents)
lentiviral-packaging-tool Transfection Reagent Mycoplasma Removal Reagent Antibiotic Gene Knockout Kit Polybrene Switch-On Reagent Staphylococcal Enterotoxin E
Insights
Press Release
Promotion
Event
Citations Database
Handbook
Product Mannual
About
History
Honor
Contact
Careers
Search
CN
Search
Home
Products
Plasmid Cell lines Molecular Reference Standards Reporter gene detection-related reagents Lentivirus Proteins Pseudovirus control material Reagents related to cell function detection and analysis Adeno-Associated Virus (AAV) Antibodies Pseudovirus Genoagent (Brand name of reagents)
Services
Lentivirus Adeno-associated Virus Cell Line Development Cell-based Assay Plasmid DNA Preparation Services Protein Expression Antibody Services Reporter Gene Detection Services
Activity
Resource
Citations Database Handbook Product Mannual
News
Genomeditech
About History Honor Contact Careers
Insights
Press Release
Current position：News > Insights
Insights
GLP-1 Landscape Shift: The Rise of Oral Weight-Loss Therapies
Metabolic disease treatment is entering a new era.

While GLP-1 therapies continue to lead, emerging targets like GIPR, GCGR, FGF21, Amylin, and ActRII are driving the shift toward multi-target strategies. At the same time, oral GLP-1 drugs are intensifying competition between Novo Nordisk and Eli Lilly.

Where is the field heading next? Read the full article for key insights.
2026-04-15
TSLP: A Promising Next-Generation Target in Autoimmune Diseases
TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.
2026-04-09
The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology
The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.
2026-03-25
IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?
IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?
2026-03-11
IL-23: A Rising Target in Autoimmune Disease
2026-02-27
TNF-α: Renewed Focus in Autoimmune Disease Therapy
Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.
2026-02-05
PD-1 Agonists: Insights into Their Growing Impact
PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.
2026-01-29
Will B7-H3 Become the Next Major ADC Target?
The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.
2026-01-22
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
2025-12-24
First 1 2 3 4 5 Last
Total 7 Page
Jump
Current position：News > Insights
classify
Insights
GLP-1 Landscape Shift: The Rise of Oral Weight-Loss Therapies
Metabolic disease treatment is entering a new era.

While GLP-1 therapies continue to lead, emerging targets like GIPR, GCGR, FGF21, Amylin, and ActRII are driving the shift toward multi-target strategies. At the same time, oral GLP-1 drugs are intensifying competition between Novo Nordisk and Eli Lilly.

Where is the field heading next? Read the full article for key insights.
2026-04-15
TSLP: A Promising Next-Generation Target in Autoimmune Diseases
TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.
2026-04-09
The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology
The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.
2026-03-25
IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?
IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?
2026-03-11
IL-23: A Rising Target in Autoimmune Disease
2026-02-27
TNF-α: Renewed Focus in Autoimmune Disease Therapy
Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.
2026-02-05
PD-1 Agonists: Insights into Their Growing Impact
PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.
2026-01-29
Will B7-H3 Become the Next Major ADC Target?
The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.
2026-01-22
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
2025-12-24
MORE
Insights
Press Release
Products
Plasmid Lentivirus Adeno-associated virus Cell lines Proteins Antibodies Molecular Reference Standards Pseudovirus control material pseudovirus Reporter gene detection-related reagents Reagents related to cell function detection and analysis Genoagent (Brand name of reagents)
Services
Lentivirus Cell line Development Protein Expression Plasmid DNA Preparation Services Adeno-associated Virus Cell-based Assay Antibody Services Reporter Gene Detection Services
Resource
Citations Database Download
About Genomeditech
About History Honor Contact Careers
Social Media
Linkedin
Twitter
Partner Platform
Scientist
Toll-free hotline：400-627-9288
Email address：mkt.genomeditech@gmail.com
Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai
Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.
Privacy Policy
Message consultation
reset
submit
Toll-free hotline：400-627-9288
Email address：mkt.genomeditech@gmail.com
Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai
Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.
Message
Message consultation
reset
submit